Oral disease-modifying therapies for multiple sclerosis: are we there yet?
- PMID: 20574638
- PMCID: PMC2970508
- DOI: 10.1007/s11910-010-0126-2
Oral disease-modifying therapies for multiple sclerosis: are we there yet?
Conflict of interest statement
No potential conflicts of interest relevant to this article were reported.
Comment on
-
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Clinical Trial.
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Clinical Trial.
References
-
- Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. - PubMed
-
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415. - PubMed
-
- Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426. - PubMed
-
- Comi G, O’Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16:197–207. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
